Emerging therapy for the treatment of mantle cell lymphoma.

@article{Rajguru2014EmergingTF,
  title={Emerging therapy for the treatment of mantle cell lymphoma.},
  author={Saurabh A. Rajguru and Brad S Kahl},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2014},
  volume={12 9},
  pages={
          1311-8; quiz 1318
        }
}
Mantle cell lymphoma (MCL) is a heterogenous disease with historically relative poor outcomes. However, new treatment strategies seem to be improving the prognosis for patients. Although no universally accepted standard of care exists, options for patients with newly diagnosed MCL include intensive and nonintensive strategies. Generally, intensive strategies produce more durable remissions and are selected for younger patients, whereas nonintensive strategies are most appropriate for older… CONTINUE READING

Figures, Tables, and Topics from this paper.

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Phase 2 study of VcR - CVAD with maintenance rituximab for untreated mantle cell lymphoma : an Eastern Cooperative Oncology Group study ( E 1405 )

R Forstpointner, M Unterhalt, M Dreyling
  • Blood
  • 2014

Phase 2 study of VcR - CVAD with maintenance rituximab for untreated mantle cell lymphoma : an Eastern Cooperative Oncology Group study ( E 1405 )

R Forstpointner, M Unterhalt, M Dreyling
  • Blood
  • 2014